234 related articles for article (PubMed ID: 29708923)
1. Predicting cardiovascular disease in familial hypercholesterolemia.
Paquette M; Baass A
Curr Opin Lipidol; 2018 Aug; 29(4):299-306. PubMed ID: 29708923
[TBL] [Abstract][Full Text] [Related]
2. Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?
Mata P; Alonso R; Pérez de Isla L
Curr Opin Lipidol; 2018 Dec; 29(6):445-452. PubMed ID: 30382952
[TBL] [Abstract][Full Text] [Related]
3. The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia.
Paquette M; Dufour R; Baass A
J Clin Lipidol; 2017; 11(1):80-86. PubMed ID: 28391914
[TBL] [Abstract][Full Text] [Related]
4. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia.
Paquette M; Chong M; Thériault S; Dufour R; Paré G; Baass A
J Clin Lipidol; 2017; 11(3):725-732.e5. PubMed ID: 28456682
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE.
Paquette M; Brisson D; Dufour R; Khoury É; Gaudet D; Baass A
J Clin Lipidol; 2017; 11(5):1161-1167.e3. PubMed ID: 28801029
[TBL] [Abstract][Full Text] [Related]
6. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.
Bianconi V; Banach M; Pirro M;
Trends Cardiovasc Med; 2021 May; 31(4):205-215. PubMed ID: 32205033
[TBL] [Abstract][Full Text] [Related]
7. Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome.
Badimon L; Padró T; Cubedo J
Curr Opin Lipidol; 2017 Oct; 28(5):427-433. PubMed ID: 28682808
[TBL] [Abstract][Full Text] [Related]
8. Predictors of cardiovascular risk in familial hypercholesterolemia.
Romero-Jiménez MJ; Mansilla-Rodríguez ME; Gutiérrez-Cortizo EN
Curr Opin Lipidol; 2023 Dec; 34(6):272-277. PubMed ID: 37769168
[TBL] [Abstract][Full Text] [Related]
9. Familial hypercholesterolemia: experience from the French-Canadian population.
Paquette M; Genest J; Baass A
Curr Opin Lipidol; 2018 Apr; 29(2):59-64. PubMed ID: 29356704
[TBL] [Abstract][Full Text] [Related]
10. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis.
Oosterveer DM; Versmissen J; Yazdanpanah M; Hamza TH; Sijbrands EJ
Atherosclerosis; 2009 Dec; 207(2):311-7. PubMed ID: 19439299
[TBL] [Abstract][Full Text] [Related]
11. Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?
Santos RD
Curr Opin Lipidol; 2017 Apr; 28(2):130-135. PubMed ID: 28059950
[TBL] [Abstract][Full Text] [Related]
12. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia.
Koeijvoets KC; van der Net JB; Dallinga-Thie GM; Steyerberg EW; Mensink RP; Kastelein JJ; Sijbrands EJ; Plat J
Atherosclerosis; 2009 Jun; 204(2):453-8. PubMed ID: 18977479
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature.
Wong B; Kruse G; Kutikova L; Ray KK; Mata P; Bruckert E
Clin Ther; 2016 Jul; 38(7):1696-709. PubMed ID: 27261205
[TBL] [Abstract][Full Text] [Related]
14. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia.
Paquette M; Dufour R; Baass A
J Clin Lipidol; 2018; 12(2):383-389.e1. PubMed ID: 29290540
[TBL] [Abstract][Full Text] [Related]
15. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia.
Jansen AC; van Aalst-Cohen ES; Tanck MW; Cheng S; Fontecha MR; Li J; Defesche JC; Kastelein JJ
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1475-81. PubMed ID: 15879303
[TBL] [Abstract][Full Text] [Related]
16. Annexin A5 haplotypes in familial hypercholesterolemia: lack of association with carotid intima-media thickness and cardiovascular disease risk.
Hiddink L; Dallinga-Thie GM; Hovingh GK; de Visser MC; Peer PG; Stalenhoef AF; van Heerde WL
Atherosclerosis; 2015 Feb; 238(2):195-200. PubMed ID: 25525746
[TBL] [Abstract][Full Text] [Related]
17. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia.
Bea AM; Civeira F; Jarauta E; Lamiquiz-Moneo I; Pérez-Calahorra S; Marco-Benedí V; Cenarro A; Mateo-Gallego R
Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):551-558. PubMed ID: 28215923
[TBL] [Abstract][Full Text] [Related]
20. My Approach to the Patient With Familial Hypercholesterolemia.
Safarova MS; Kullo IJ
Mayo Clin Proc; 2016 Jun; 91(6):770-86. PubMed ID: 27261867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
